Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
846 Results for "
Drug Intermediate
" in MedChemExpress (MCE) Product Catalog:
Products (846)
846 Results for "Drug Intermediate" in MCE Product Catalog:
2
2 Cited Publications
Target:
Research Areas:
PAR-2-IN intermediate-1 is a drug intermediate that can be used to synthesize inhibitors of the PAR-2 signaling pathway .
2
2 Cited Publications
Cat. No.: HY-W012860
CAS No.: 104-87-0
2
1
Target:
Research Areas:
4-Hydroxy-2-naphthoic acid is a drug intermediate for synthesis of various active compounds.
1
1 Cited Publications
Cat. No.: HY-N8651
CAS No.: 86383-39-3
Target:
Research Areas:
2'-Hydroxy-3,4-dimethoxydihydrochalcone is a drug intermediate for synthesis of various active compounds.
1
1 Cited Publications
Cat. No.: HY-41514
CAS No.: 1627924-19-9
Target:
Research Areas:
3-Iodo-1-tetrahydropyran-2-yl-pyrazole-4-carbaldehyde is a drug intermediate for synthesis of various active compounds.
1
1 Cited Publications
Cat. No.: HY-W007466
CAS No.: 504-02-9
1
1 Cited Publications
Cat. No.: HY-I0198
CAS No.: 385425-15-0
Synonyms: 1-(4-Iodophenyl)piperidin-2-one
Target:
Research Areas:
1-(4-Iodophenyl)-2-piperidinone (1-(4-Iodophenyl)piperidin-2-one) is a drug intermediate for synthesis of various active compounds.
1
1 Cited Publications
Cat. No.: HY-W002011
CAS No.: 93-10-7
Target:
1
1 Cited Publications
Cat. No.: HY-160807
CAS No.: 2769152-95-4
Target:
Research Areas:
DBM-GGFG-NH-O-CO-Exatecan (Example 4, Compound 14) is a conjugate of an ADC drug toxin molecule and a linker. DBM-GGFG-NH-O-CO-Exatecan is a complete antibody-drug conjugate intermediate that integrates a potent camptothecin-based toxin, a cleavable peptide linker (GGFG), and a reactive terminus that can directly conjugate to antibodies .
Cat. No.: HY-P4192
CAS No.: 1817857-75-2
Target:
Research Areas:
Target:
Research Areas:
GPX4-IN-1 intermediate-1 is a Drug Intermediate that can be used in organic synthesis-related research. GPX4-IN-1 intermediate-1 participates in the synthesis of GPX4-IN-1 (HY-138544), and GPX4-IN-1 can be applied in cancer-related research .
Cat. No.: HY-32742
CAS No.: 128071-98-7
Cat. No.: HY-21622
CAS No.: 39093-93-1
Target:
Research Areas:
Thiomorpholine 1,1-dioxide is a drug intermediate for synthesis of various active compounds.
Cat. No.: HY-43384
CAS No.: 40510-81-4
Synonyms: Tenofovir Impurity 66
Target:
Research Areas:
Chloromethyl methyl carbonate (Tenofovir Impurity 66) is a drug intermediate for synthesis of various active compounds.
Cat. No.: HY-W010611
CAS No.: 541-47-9
Synonyms: 3-Methylcrotonic acid; 3-Methylbut-2-enoic acid
Target:
Cat. No.: HY-23925
CAS No.: 63600-35-1
Target:
Research Areas:
2-Vinylphenyl acetate is a drug intermediate for synthesis of various active compounds.
Cat. No.: HY-W061628
CAS No.: 209329-11-3
Target:
Research Areas:
(R)-Azetidin-2-ylmethanol is a drug intermediate for synthesis of various active compounds.
Cat. No.: HY-W105369
CAS No.: 3724-55-8
Target:
Research Areas:
Methyl but-3-enoate is a drug intermediate for synthesis of various active compounds.
Cat. No.: HY-W012971
CAS No.: 2508-29-4
Target:
Research Areas:
5-Amino-1-pentanol is a primary amine that serves as an intermediate in organic/biochemical synthesis for the derivatization of drug molecules and bioactive molecules, as well as an intermediate for radiological contrast agents .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
